Extended spectrum of cancers in PTEN hamartoma tumor syndrome.

IF 6.8 1区 医学 Q1 ONCOLOGY NPJ Precision Oncology Pub Date : 2025-03-06 DOI:10.1038/s41698-025-00847-3
Lamis Yehia, Gilman Plitt, Ann M Tushar, Darren Liu, Julia Joo, Ying Ni, Sujata Patil, Charis Eng
{"title":"Extended spectrum of cancers in PTEN hamartoma tumor syndrome.","authors":"Lamis Yehia, Gilman Plitt, Ann M Tushar, Darren Liu, Julia Joo, Ying Ni, Sujata Patil, Charis Eng","doi":"10.1038/s41698-025-00847-3","DOIUrl":null,"url":null,"abstract":"<p><p>PTEN hamartoma tumor syndrome (PHTS) is associated with increased lifetime risks of breast, thyroid, kidney, endometrial, and colorectal cancers, as well as melanoma (collectively, component cancers). We sought to characterize non-component cancers (NCC) in PHTS. Of 701 research participants with PHTS, 340 (49%) had cancer, with 101 (30%) having at least one NCC. Interestingly, 71 (70%) of those with NCC had at least one other PHTS component malignancy. Patients with pathogenic PTEN variants showed higher risks for prostate cancer and soft tissue sarcomas at younger ages than the general population. A literature survey showed independent cases of NCC in PHTS, with PTEN-related molecular changes including second-hit somatic PTEN alterations in a subset of various specimens. We recommend increased awareness regarding NCC in individuals with PHTS, particularly increased risks for prostate cancer and sarcoma. Further studies are needed to define age-related penetrance and accordingly, the appropriate strategies for cancer risk management.</p>","PeriodicalId":19433,"journal":{"name":"NPJ Precision Oncology","volume":"9 1","pages":"61"},"PeriodicalIF":6.8000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885834/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Precision Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41698-025-00847-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

PTEN hamartoma tumor syndrome (PHTS) is associated with increased lifetime risks of breast, thyroid, kidney, endometrial, and colorectal cancers, as well as melanoma (collectively, component cancers). We sought to characterize non-component cancers (NCC) in PHTS. Of 701 research participants with PHTS, 340 (49%) had cancer, with 101 (30%) having at least one NCC. Interestingly, 71 (70%) of those with NCC had at least one other PHTS component malignancy. Patients with pathogenic PTEN variants showed higher risks for prostate cancer and soft tissue sarcomas at younger ages than the general population. A literature survey showed independent cases of NCC in PHTS, with PTEN-related molecular changes including second-hit somatic PTEN alterations in a subset of various specimens. We recommend increased awareness regarding NCC in individuals with PHTS, particularly increased risks for prostate cancer and sarcoma. Further studies are needed to define age-related penetrance and accordingly, the appropriate strategies for cancer risk management.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PTEN错构瘤肿瘤综合征中癌症的扩展谱。
PTEN错构瘤肿瘤综合征(PHTS)与乳腺癌、甲状腺癌、肾癌、子宫内膜癌、结直肠癌以及黑色素瘤(统称为组成癌)的终生风险增加有关。我们试图描述PHTS的非成分癌(NCC)。在701名患有PHTS的研究参与者中,340名(49%)患有癌症,101名(30%)患有至少一种NCC。有趣的是,71例(70%)NCC患者至少有一种其他PHTS成分恶性肿瘤。具有致病性PTEN变异的患者在年轻时患前列腺癌和软组织肉瘤的风险高于一般人群。一项文献调查显示,在PHTS中存在独立的NCC病例,PTEN相关的分子变化包括在不同标本的子集中出现的第二击体细胞PTEN改变。我们建议提高PHTS患者对NCC的认识,特别是前列腺癌和肉瘤的风险增加。需要进一步的研究来确定与年龄相关的外显率,并相应地制定适当的癌症风险管理策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.90
自引率
1.30%
发文量
87
审稿时长
18 weeks
期刊介绍: Online-only and open access, npj Precision Oncology is an international, peer-reviewed journal dedicated to showcasing cutting-edge scientific research in all facets of precision oncology, spanning from fundamental science to translational applications and clinical medicine.
期刊最新文献
Author Correction: Epigenetic determinants of an immune-evasive phenotype in HER2-low triple-negative breast cancer. Risk assessment of secondary primary malignancies: results from two large prospective European cohorts. AI-driven body composition atlas reveals its association with NSCLC immunotherapy outcome and molecular background: a multicenter study. A comprehensive foundation model for generalizable cytogenetics in precision oncology with CHROMA. Finding the most promising indications for novel treatments in oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1